ProJenX

Artificial Intelligence · Health Care

Overview

ProJenX's mission is to make prosetin, a scientifically validated, first-in-class MAP4 kinase inhibitor, available for ALS and other neurodegenerative diseases.

Funding and backers

Total raised
$5.1M
1 round on record
Latest round
$5.1M
Venture round · Dec 2021 · 4 yr ago
Team
51-200
employees, estimated range
The money's age
Long since its last round
58 months since the last round · not hiring
Momentum
0/100
no fresh signals
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Dec 22, 2021 Raised a round Venture round $5.1M · SEC Form D 2021 Founded
Funding rounds
RoundDateAmountInvestorsSource
Venture round Dec 2021 $5.1M — SEC Form D
Registers and programsofficial lists and records that name the company
Legal entity ProJenX, Inc. SEC Form D
Founders and leadersfrom filings, registers and the company's site
Joni ManciniExecutive OfficerSEC Form D
Investors in similar startupsfunds that back the companies most like this one
Y Combinator
backs Synapticure
GV
backs Synapticure
Parkwalk Advisors
backs Cambridge Vision Technology
RA Capital Management
backs Synapticure
Cambridge Enterprise
backs Cambridge Vision Technology
OrbiMed
backs Vanqua Bio
Similar startupsby what they do, their industry and backers
Esitu SolutionsVenture round · 5 yr ago · Founded 2020
Esitu Solutions provides scientifically validated driver assessment and training tools for employees who drive for work. Learn more about…
CasInvent PharmaFounded 2020
CasInvent Pharma | CasInvent Pharma. Fighting resistant tumors with best-in-class inhibitors of casein kinase 1 (CK1).
Cambridge Vision Technology
Who are we Cambridge Vision Technology (CVT) is an integrated medical device company focused on delivering scientifically validated…
Cognition Therapeutics, Inc.
Advancing Accessible Solutions for Complex Neurodegenerative Diseases. Protecting neurons to advance treatment for neurodegenerative…
CND Life SciencesSeries A $13.5M · 18 mo ago · Founded 2017
CND advances neurodiagnostics through skin biopsy testing, including the Syn-One Test, for neurodegenerative diseases.
Natural Health Supplements | OmniActive Health TechnologiesFounded 2019 · 201-500 employees
At OmniActive, we deliver innovative, scientifically validated, and nature-based natural ingredients to nutrition brands around the world…

Financials

Total raised
$5.1M
Latest round
Venture - Series Unknown
Funding rounds
1
Funding rounds
Round Announced Amount
Venture - Series Unknown 2021 $5.1M Details

People

Joni Mancini
Executive Officer
SEC Form D
Eric Heil
Director
SEC Form D
John Prufeta
Director
SEC Form D
Valerie Estess
Director
SEC Form D
Hynek Wichterle
Director
SEC Form D
Names and roles come from public filings, company registers and the company's own site. Is this you? Correct or remove · How we handle this data